Benzinga · Aug 24, 2026
Why Is Capricor Therapeutics Stock Trading Higher on Monday?
Capricor stock rises as FDA extends its deramiocel review to Nov. 22 following new Phase 3 HOPE-3 data and an advisory panel setback.
NASDAQ · CAPR
Capricor Therapeutics, Inc.
Healthcare · Biotechnology
$9.28
Up+$0.17 (+1.83%)
Updated Sep 4, 2026, 5:43 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.24B
- P/E ratio
- -17.75
- Dividend yield
- 0.00%
- 52-week range
- $2.96 – $40.37
- Volume
- 4.06M
- Avg. volume
- 2.79M
Price performance
CAPR price history
1M range · 21 trading sessions · Daily adjusted prices
CAPR closed at $9.28 after 21 trading sessions, up 122.01% for the selected period.
- Last close
- $9.28
- Period change
- +122.01%
- Period low
- $3.85
- Period high
- $10.06
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 3, 2026 | $9.83 | $9.93 | $9.14 | $9.28 | 4.06M |
| Sep 2, 2026 | $10.07 | $10.65 | $9.60 | $9.89 | 5.17M |
| Sep 1, 2026 | $10.77 | $11.00 | $9.85 | $10.01 | 6.31M |
| Aug 31, 2026 | $9.495 | $10.27 | $9.065 | $9.91 | 4.56M |
| Aug 28, 2026 | $9.73 | $10.20 | $9.47 | $9.59 | 5.19M |
| Aug 27, 2026 | $9.19 | $10.61 | $8.90 | $10.06 | 12.05M |
| Aug 26, 2026 | $8.29 | $9.88 | $8.05 | $9.36 | 12.04M |
| Aug 25, 2026 | $7.25 | $8.60 | $7.25 | $8.29 | 17.63M |
| Aug 24, 2026 | $8.03 | $8.03 | $6.34 | $6.80 | 20.09M |
| Aug 21, 2026 | $6.81 | $7.08 | $6.01 | $6.29 | 8.36M |
| Aug 20, 2026 | $7.66 | $7.82 | $6.83 | $6.835 | 8.11M |
| Aug 19, 2026 | $7.19 | $7.99 | $7.14 | $7.98 | 8.57M |
| Aug 18, 2026 | $7.50 | $8.29 | $6.7641 | $7.08 | 8.54M |
| Aug 17, 2026 | $6.87 | $7.59 | $6.59 | $7.45 | 19.22M |
| Aug 14, 2026 | $7.66 | $8.15 | $6.04 | $6.65 | 66.33M |
| Aug 13, 2026 | $4.18 | $4.42 | $4.14 | $4.21 | 16.75M |
| Aug 12, 2026 | $3.95 | $4.30 | $3.90 | $4.19 | 2.75M |
| Aug 11, 2026 | $3.85 | $3.998 | $3.73 | $3.93 | 3.33M |
| Aug 10, 2026 | $4.04 | $4.105 | $3.805 | $3.85 | 3.09M |
| Aug 7, 2026 | $4.16 | $4.70 | $4.05 | $4.09 | 3.62M |
| Aug 6, 2026 | $3.88 | $4.21 | $3.8681 | $4.18 | 3.21M |
Latest CAPR news
The latest Smart Investors Daily articles mentioning CAPR.
Stock researchCompany · Overview
CAPR research
Overview
Company profile and research snapshot.
Company profile
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $45.00
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | Piper Sandler | Overweight | — |
| Aug 14, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 31, 2026 | Jones Trading | Hold | — |
| Jul 30, 2026 | Piper Sandler | Neutral | — |
| Jul 30, 2026 | Cantor Fitzgerald | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 24, 2026
Capricor Therapeutics Says FDA Extends PDUFA Target Action Date For Its BLA For Deramiocel, Investigational Cell Therapy For Duchenne Muscular Dystrophy, From August 22 To November 22
– New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication –SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Capricor
Benzinga · Aug 21, 2026
Activist Investor Sounds Alarm on Capricor’s Cash Burn
Kaos Capital demands a governance reset and cash preservation at Capricor Therapeutics (NASDAQ: CAPR) as expenses rise.
Benzinga · Aug 21, 2026
Kaos Capital Plans To Nominate Two Independent Directors On Capricor Therapeutics' Board; To Seek Board-Led M&A, Strategic Alternatives Committee
Kaos Capital Ltd. ("Kaos Capital," "we," or "us"), a significant and growing shareholder of Capricor Therapeutics, Inc. (NASDAQ:CAPR) ("Capricor" or the "Company"), today issued a
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
